58 FINANCIAL REPORT NOTES TO THE FINANCIAL STATEMENTS CONTINUED 30 June 2022 Note 11. Trade & other receivables - non-current Consolidated 2022 2021 $ $ Non-current assets GBM Agile deposit 7,257,947 6,650,705 Corporate credit card deposit 42,923 42,923 7,300,870 6,693,628 The GBM Agile deposit was advanced to GCAR at the start of the GBM Agile trial, and is refundable if not utilised against trial expenses. The amount will be allocated against expenditure towards the latter end of the trial. Note 12. Other assets Consolidated 2022 2021 $ $ Current assets Prepayments 156,153 1,719,696 Note 13. Intangibles Consolidated 2022 2021 $ $ Non-current assets Licensing agreement - Paxalisib 16,407,788 16,407,788 Less: Accumulated amortisation (6,166,344) (5,081,993) 10,241,444 11,325,795 Licensing agreement - EVT-801 10,857,763 10,857,763 Less: Accumulated amortisation (1,049,555) (180,965) 9,808,208 10,676,798 20,049,652 22,002,593 Reconciliations Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below: EVT801 licensing agreement Paxalisib licensing agreement Total Consolidated $ $ $ Balance at 1 July 2020 - 12,410,139 12,410,139 Additions 10,857,763 - 10,857,763 Amortisation expense (180,965) (1,084,344) (1,265,309) Balance at 30 June 2021 10,676,798 11,325,795 22,002,593 Amortisation expense (868,590) (1,084,351) (1,952,941) Balance at 30 June 2022 9,808,208 10,241,444 20,049,652
RkJQdWJsaXNoZXIy MjE2NDg3